Market Research Logo

Polycythemia Vera - Pipeline Review, H1 2015


Attention: There is an updated edition available for this report.

Polycythemia Vera - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Polycythemia Vera - Pipeline Review, H1 2015’, provides an overview of the Polycythemia Vera’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Polycythemia Vera and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Polycythemia Vera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Polycythemia Vera pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Polycythemia Vera
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Polycythemia Vera pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Polycythemia Vera Overview
Therapeutics Development
Pipeline Products for Polycythemia Vera - Overview
Pipeline Products for Polycythemia Vera - Comparative Analysis
Polycythemia Vera - Therapeutics under Development by Companies
Polycythemia Vera - Therapeutics under Investigation by Universities/Institutes
Polycythemia Vera - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Polycythemia Vera - Products under Development by Companies
Polycythemia Vera - Products under Investigation by Universities/Institutes
Polycythemia Vera - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Company
Galena Biopharma, Inc.
Incyte Corporation
Italfarmaco S.p.A.
miRagen Therapeutics, Inc.
Novartis AG
Onconova Therapeutics, Inc.
PharmaEssentia Corporation
Polycythemia Vera - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
anagrelide hydrochloride CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dasatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erismodegib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGN-4893 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
peginterferon alfa-2b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rigosertib sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit JAK for Oncology and Hematological Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Polycythemia Vera - Recent Pipeline Updates
Polycythemia Vera - Dormant Projects
Polycythemia Vera - Discontinued Products
Polycythemia Vera - Product Development Milestones
Featured News & Press Releases
Jan 28, 2015: Incyte Announces Publication of Phase III RESPONSE Trial in Patients with Polycythemia Vera in New England Journal of Medicine
Jan 28, 2015: Novartis announces study in NEJM showing Jakavi was superior to standard therapy in rare blood cancer polycythemia vera
Jan 23, 2015: Incyte Earns $25 Million Milestone as Jakavi (ruxolitinib) Recommended for Approval in Europe for Polycythemia Vera
Dec 04, 2014: FDA Approves Jakafi (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera
Dec 02, 2014: Multiple Data Presentations at the 2014 American Society of Hematology Annual Meeting Showcase Incyte's Leadership in the Field of Myeloproliferative Neoplasms
Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
Aug 05, 2014: FDA Accepts Supplemental New Drug Application for Jakafi (ruxolitinib) and Priority Review Granted
Jul 23, 2014: Incyte Announces Top-Line Results from RELIEF Trial of Ruxolitinib in Patients with Polycythemia Vera
Jun 03, 2014: Pivotal Phase III Data in Polycythemia Vera Show that Jakafi (ruxolitinib) Achieved Superior Disease Control Compared to Best Available Therapies
Mar 07, 2014: Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Polycythemia Vera, H1 2015
Number of Products under Development for Polycythemia Vera - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Polycythemia Vera - Pipeline by Bristol-Myers Squibb Company, H1 2015
Polycythemia Vera - Pipeline by Galena Biopharma, Inc., H1 2015
Polycythemia Vera - Pipeline by Incyte Corporation, H1 2015
Polycythemia Vera - Pipeline by Italfarmaco S.p.A., H1 2015
Polycythemia Vera - Pipeline by miRagen Therapeutics, Inc., H1 2015
Polycythemia Vera - Pipeline by Novartis AG, H1 2015
Polycythemia Vera - Pipeline by Onconova Therapeutics, Inc., H1 2015
Polycythemia Vera - Pipeline by PharmaEssentia Corporation, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Polycythemia Vera Therapeutics - Recent Pipeline Updates, H1 2015
Polycythemia Vera - Dormant Projects, H1 2015
Polycythemia Vera - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Polycythemia Vera, H1 2015
Number of Products under Development for Polycythemia Vera - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report